Abbreviation
HLA-I: human leukocyte antigen class I; HLA-I LOH: loss of
heterozygosity in human leukocyte class I; WES: whole exome sequencing;
TMB: tumor mutation burden; MSI: microsatellite instability; DDR: DNA
damage response; CPF: check point factor; FA: Fanconi anemia; ICI:
immune checkpoint inhibitor; PD-L1: programmed cell death-ligand 1;
MHC-I: major histocompatibility complex class I; NK cell: natural killer
cell; SqCC: squamous cell carcinoma; BRCA: breast invasive carcinoma;
CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma;
CRC: colorectal carcinoma; KIPAN: pan-kidney cohort; LIHC: liver
hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous
cell carcinoma; NSCLC: non-small cell lung cancer; OV: ovarian serous
cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate
adenocarcinoma; STES: stomach and esophageal carcinoma; UCEC: uterine
corpus endometrial carcinoma.